The E3 ubiquitin ligase Cbl-b is a novel target in immune-oncology, with critical roles in regulating T-cell activation and signaling pathways. By facilitating the ubiquitination and degradation of key signaling proteins, Cbl-b modulates immune responses, maintaining immune homeostasis and preventing unwarranted T-cell proliferation. The therapeutic potential of Cbl-b as a cancer immunotherapy target is underscored by its contribution to an immunosuppressive tumor microenvironment, with efforts currently underway to develop small-molecule inhibitors.

Riccardo Fusco

Zeinab Saedi

Imma Capriello

Andriy Lubskyy

Alexander Dömling

Expert Opinion on Therapeutic Patents

EXPERT OPINION ON THERAPEUTIC PATENTS (ISSN 1354-3776 [PRINT], 1744-7674 [ELECTRONIC]) 是 MEDLINE 索引、同行评审的国际期刊，发表关于近期药物专利权利要求的评论文章，为未来发展提供专家意见，在科学文献的背景下。编辑欢迎：评论涵盖最近关于具有治疗潜力的化合物或应用的专利权利要求，包括具有特定分子靶标的生物治疗药物和小分子药物；和特定治疗领域的专利申请趋势专利评估审查个别专利的目的和化学和生物权利要求与知识产权相关问题的观点观众包括制药行业的科学家、管理人员和决策者以及与研发密切相关的其他人，例如我们的生物科学期刊，在此处登录以开始访问，最新的两卷完整卷免费提供给您 14 天。

Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [PRINT], 1744-7674 [ELECTRONIC]) is an international peer-reviewed journal indexed in MEDLINE, focusing on commentaries regarding recent drug patent claims to provide expert insights for future developments. The editorial team welcomes reviews covering patent claims related to compounds or applications with therapeutic potential, including biotherapeutics and small molecules targeting specific molecular pathways, as well as trends in patent applications within specific therapeutic areas. The journal also evaluates the purposes of individual patents and discusses issues related to chemical and biological claims and intellectual property. The audience includes scientists, managers, and decision-makers in the pharmaceutical industry, as well as other professionals closely related to research and development. We offer free access to the latest two complete volumes for 14 days.

《Expert Opinion on Therapeutic Patents》（ISSN 1354-3776 [印刷版]，1744-7674 [电子版]）是一本国际同行评审的期刊，收录于MEDLINE，专注于近期药物专利的评论文章，旨在为未来的发展提供专家见解。编辑欢迎关于具有治疗潜力的化合物或应用的专利权利要求的评论，包括针对特定分子靶标的生物治疗药物和小分子药物，以及特定治疗领域的专利申请趋势。期刊还评估个别专利的目的，探讨与化学和生物权利要求及知识产权相关的问题。读者包括制药行业的科学家、管理人员和决策者，以及与研发密切相关的其他专业人士。我们提供最新的两卷完整卷，供您免费访问14天。

Category	Quartile
医学	2
医学, 药物化学	2
医学, 药学	2

Expert opinion on therapeutic patents - manuscript ID EOTP-2024-ST-0024 has been submitted online

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
PHARMACOLOGY & PHARMACY	1